DNA Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

DNA, or deoxyribonucleic acid, is a molecule that contains the genetic instructions for the development, functioning, and reproduction of all living organisms. Its primary mechanism of action involves encoding genetic information through a sequence of nucleotides and serving as a template for the synthesis of RNA and proteins. DNA has a wide range of applications in various disease indications, including genetic testing, forensics, and research on inherited diseases and genetic disorders. According to the World Health Organization (WHO), genetic testing using DNA analysis plays a crucial role in diagnosing and managing genetic diseases. In Europe, approximately 5,000 genetic tests are available for various conditions, including inherited cancers, cardiovascular diseases, and rare genetic disorders. In the United States, the prevalence of genetic diseases is estimated to be around 10%, with conditions such as cystic fibrosis, muscular dystrophy, and sickle cell disease being prevalent.

The growth drivers of the DNA market include advancements in technology, such as next-generation sequencing, which have led to improved accuracy, scalability, and cost-effectiveness of DNA analysis. Companies such as Nippon Kayaku, Roche, UCB, PDL, Pfizer, Roche, BMS, Bayer, Servier, Vion, SymBio Pharma, Vivacitas, Denovo, EMD Serono, Eli Lilly, Imunon, UroGen, metronidazole, Arrowhead, Spectrum Pharma, UroGen, Daiichi Sankyo, CTI BioPharma, Cellectar, Meabco, Regulon, Delcath, Teva, and AstraZeneca cater in this category. Moreover, many companies are coming up with new molecules in this space. For instance, Otsuka is currently conducting a clinical trial of the drug SGI-110 for the treatment of leukemia.

Key Developments:

  • In May 2023, RenovoRx announced its intention to submit New Drug Applications both in accelerated and traditional approvals to the US FDA of Oxaliplatin for Pancreatic cancer.
  • In Oct 2020, Allarity Therapeutics received a patent allowance from the USPTO for Methods for predicting drug responsiveness in Cancer in the US

Approved DNA Molecules

  • Cisplatin
  • Gemcitabine
  • Oxaliplatin
  • Fludarabine IV
  • Cytarabine
  • Temozolomide
  • Azacitidine
  • Bendamustine
  • Daunorubicin
  • Hydroxyurea
  • Mitomycin
  • Entecavir
  • Idarubicin Hydrochloride
  • Thiotepa
  • Carmustine
  • Mercaptopurine
  • Dacarbazine
  • Clofarabine
  • Metronidazole oral
  • Acyclovir
  • Starasid (cytarabine ocfosfate)
  • Mylotarg (gemtuzumab ozogamicin)
  • Cytovene (ganciclovir)
  • Yondelis (trabectedin)
  • Lonsurf (trifluridine
  • Bleomycin
  • Thioguanine
  • Betadine (povidone iodine)
  • Vyxeos (cytarabine)

DNA Pipeline Molecules

  • Guadecitabine (SGI-110)
  • DC Bead (E7040)
  • Ciprofloxacin (Q3939)
  • Irofulven-1 (LP-100)
  • Peposertib (M3814)
  • Samotolisib (LY3023414)
  • ARC-520
  • Sapacitabine (CYC682)
  • Brostallicin (PNU-166196)
  • Iopofosine I-131 (CLR 131)
  • Picoplatin (AMD 473)
  • Trastuzumab duocarmazine (SYD985)
  • BP-C1
  • SG 2000  

Clinical Activity and Development of DNA

In the DNA space, more than 20 companies are conducting more than 400 clinical trials in this category of drugs. For instance,

  • In May 2023, Allarity Therapeutics released updated efficacy data from a phase I/II trial of lipid-encapsulated cisplatin in Solid tumors
  • In June 2023, LiPlasome Pharma presented updated efficacy and adverse events data from the phase I/II LiPlaCis trial in Solid tumors at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)

Product Name

Total Studies

Guadecitabine (SGI-110)

36

DC Bead (E7040)

21

Ciprofloxacin (Q3939)

21

Irofulven-1 (LP-100)

20

Peposertib (M3814)

17

Samotolisib (LY3023414)

17

ARC-520

9

Sapacitabine (CYC682)

9

Brostallicin (PNU-166196)

8

Iopofosine I-131 (CLR 131)

8

Picoplatin (AMD 473)

8

Trastuzumab duocarmazine (SYD985)

7

BP-C1

6

SG 2000

6

Target Indication Analysis of DNA

DNA, or deoxyribonucleic acid, has emerged as a promising target indication in various fields. In healthcare, it plays a crucial role in the diagnosis, treatment, and prevention of genetic disorders, cancers, and infectious diseases. DNA-based diagnostics enable precise identification of genetic mutations, aiding in personalized medicine approaches. Additionally, therapeutic interventions such as gene therapy and gene editing utilize DNA to correct or modify genetic defects. In agriculture, DNA technologies contribute to crop improvement, disease resistance, and enhanced productivity. Furthermore, DNA forensics assists in criminal investigations and the identification of human remains. The versatile applications of DNA make it a valuable target indication with immense potential for advancement in multiple sectors.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2018-2022), and forecast (2023-2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Frequently Asked Questions

DNA drugs are used in the management of genetic disorders, cancers, and infectious diseases.

Growth drivers of the DNA market include technological advancements in DNA sequencing and analysis methods, which have led to improved accuracy, speed, and cost-effectiveness of genetic testing. The declining costs of DNA sequencing have made it more accessible, leading to increased adoption and utilization across various applications.

The major players in this space are Nippon Kayaku, Roche, UCB, PDL, Pfizer, Roche, BMS, Bayer, Servier, Vion, SymBio Pharma, Vivacitas, Denovo, EMD Serono, Eli Lilly, Imunon, UroGen, metronidazole, Arrowhead, Spectrum Pharma, UroGen, Daiichi Sankyo, CTI BioPharma, Cellectar, Meabco, Regulon, Delcath, Teva, and AstraZeneca.

The DNA market faces significant restraints due to ethical concerns and regulatory challenges surrounding privacy, consent, and ownership of genetic information. Additionally, limitations in the scalability and cost-effectiveness of DNA sequencing technologies hinder the widespread adoption and utilization of genetic testing and personalized medicine.

  • Nippon Kayaku
  • Roche
  • UCB
  • PDl
  • Pfizer
  • Roche
  • BMS
  • Bayer
  • Servier
  • Vion
  • SymBio Pharma
  • Vivacitas
  • Denovo
  • EMD Serono
  • Eli Lilly
  • Imunon
  • UroGen
  • metronidazole
  • Arrowhead
  • Spectrum Pharma
  • UroGen
  • Daiichi Sankyo
  • CTI BioPharma
  • Cellectar
  • Meabco
  • Regulon
  • Delcath
  • Teva
  • AstraZeneca